comparemela.com

Lillian Chiang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Princeton s technology accelerator fund celebrates 22 startups in 10 years of fueling innovations

The Intellectual Property (IP) Accelerator Fund provides support to researchers who have made a discovery but need to conduct extra studies to demonstrate that the discovery can meet a societal need.

International Scientific Advisors Announces Evrys Bio Awarded $34 Million from DoD

Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses

(0) The DTRA Chem Bio Technologies, Vaccines and Therapeutics Division forms industry partnership with Evrys Bio to accelerate treatment for alphavirus, arenavirus and filovirus infections DOYLESTOWN, Pa., July 13, 2021 (GLOBE NEWSWIRE) Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents. The proposed drug intends to improve disease survival after exposure to one or more viruses from three families: alphaviruses, arenaviruses and filoviruses. Evrys Bio s broad-spectrum antiviral technology is based on the discovery that certain human proteins, called sirtuins, normally defend the human (host) cell from being invaded by pathogens. The novel drug will target the human SIRT-2 protein.

Investegate |Evrys Bio Announcements | Evrys Bio: Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses

Evrys Bio Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses The DTRA Chem Bio Technologies, Vaccines and Therapeutics Division forms industry partnership with Evrys Bio to accelerate treatment for alphavirus, arenavirus and filovirus infections DOYLESTOWN, Pa., July 13, 2021 (GLOBE NEWSWIRE) Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents. The proposed drug intends to improve disease survival after exposure to one or more viruses from three families: alphaviruses, arenaviruses and filoviruses. Evrys Bio’s broad-spectrum antiviral technology is based on the discovery that certain human proteins, called sirtuins, normal

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.